重组五抗原金黄色葡萄球菌疫苗的评价:随机、单中心1a/1b期临床试验
研究在健康成人中开展随机双盲安慰剂对照1a期和随机开放标签1b期试验,评价重组五抗原金黄色葡萄球菌疫苗(rFSAV)的安全性与免疫原性。1a期144人按1:1:1:1随机接受低60μg、中120μg、高240μg剂量或安慰剂,于第0、3、7、14天接种;1b期144人按1:1:1:1随机接受0-3-7、0/0-7、0/0-3-7、0/0-7-14四种免疫程序。主要终点为接种后征集性不良事件发生率;低、中、高剂量组分别有31/36(86%)、30/36(83%)、32/36(89%)报告征集性不良事件,多为轻中度;1b期剂量调整后rFSAV(90μg)在四种免疫程序中安全性更好,未报告疫苗相关严重不良事件;抗原特异性结合抗体自第7天开始升高,约第14至21天达峰,细胞免疫应答和功能性抗体也显著高于背景水平。结论认为rFSAV在健康成人中安全、耐受良好,采用非常规免疫程序可快速诱导体液和细胞免疫应答,值得关注并进一步探索。
要点
- 1a期低、中、高剂量组征集性不良事件报告率分别为31/36(86%)、30/36(83%)、32/36(89%),多为轻中度。
- 1b期剂量调整后rFSAV(90μg)在四种免疫程序中安全性更好,未报告疫苗相关严重不良事件。
- 抗原特异性结合抗体第7天开始升高,约第14至21天达峰,细胞免疫应答和功能性抗体显著高于背景水平。
核心结论
- rFSAV在健康成人中安全、耐受良好,采用非常规免疫程序可快速诱导体液和细胞免疫应答,值得关注并进一步探索。
研究设计与样本
- 随机、双盲、安慰剂对照1a期研究:144名健康参与者按1:1:1:1随机接受低剂量(60μg)、中剂量(120μg)、高剂量(240μg)疫苗或安慰剂,于第0、3、7、14天接种。
- 随机、开放标签1b期研究:144名健康参与者按1:1:1:1随机接受0-3-7、0/0-7、0/0-3-7、0/0-7-14四种免疫程序,以评估最佳策略。
- 主要研究终点为接种后征集性不良事件发生率;免疫原性终点包括接种后五种抗原特异性抗体水平、细胞免疫应答和功能性抗体。
主要发现
- 1a期低、中、高剂量组分别有31/36(86%)、30/36(83%)、32/36(89%)报告征集性不良事件,多数为轻中度。
- 1b期剂量调整后rFSAV(90μg)在四种免疫程序中安全性更好,未报告疫苗相关严重不良事件。
- 抗原特异性结合抗体自第7天开始升高,约第14至21天达峰;细胞免疫应答和功能性抗体也显著高于背景水平。
关键数值与推荐
- 1a期低剂量组征集性不良事件31/36(86%),中剂量组30/36(83%),高剂量组32/36(89%)。
- 1b期剂量调整后rFSAV为90μg,在四种免疫程序中安全性更好。
- 抗原特异性结合抗体第7天开始升高,约第14至21天达峰。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus is an important pathogen that causes hospital and community infections. To control Staphylococcus aureus infection and reduce the usage of antibiotics, we evaluated the safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine (rFSAV) in healthy adults. METHODS: We conducted a randomized, double-blind, placebo-controlled phase 1a study and a randomized, open-label phase 1b study. In phase 1a, we randomly allocated 144 healthy participants in a ratio of 1:1:1:1 to receive the low-(60 μg), middle-(120 μg), and high-dose (240 μg) vaccine or placebo at day 0, 3, 7 and 14. In phase 1b, 144 healthy participants were randomly allocated at a ratio of 1:1:1:1 to receive 0-3-7, 0/0-7, 0/0-3-7, 0/0-7-14 regimens to estimate the optimal strategy. The primary study endpoint was the incidence of solicited adverse events post-vaccination. The immunogenicity endpoints included the level of specific antibodies to five antigens after vaccination, as well as the cellular immune responses and functional antibodies. RESULTS: There were 31 (86%), 30 (83%), and 32 (89%) of 36 participants in the low-, middle-, and high-dose group reported solicited adverse events, respectively, most of the adverse events were mild or moderate. In phase 1b, the dose-adjusted rFSAV (90 μg) showed a better safety profile in the four immune procedures, and no vaccine-related serious adverse events were reported. The antigen-specific binding antibodies started to increase at day 7 and reached the peak around day 14 to 21. The cellular immune responses and functional antibodies also were substantially above background levels. CONCLUSIONS: rFSAV is safe, well tolerated in healthy adults, elicits rapid and robust specific humoral and cellular immune responses with unconventional immunization procedure in phase 1a and 1b. It deserves to be noted and further explored. CLINICAL TRIALS REGISTRATION: NCT02804711 and NCT03966040.
引用
- Zhu FC, Zeng H, Li JX, et al. Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials. Vaccine. 2022. PMID: 35473663. doi:10.1016/j.vaccine.2022.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。